 |
|
Consequences of the 1989 New York State Triplicate Benzodiazepine Prescription Regulations
Michael Weintraub, MD;
Satesh Singh, MB, BS (Hons);
Louise Byrne;
Kumar Maharaj, RPh;
Laurence Guttmacher, MD
JAMA. 1991;266(17):2392-2397.
Abstract
| |
Objective.
—Comparison of psychoactive medication prescribing and Medicaid expenditures before (1987 through 1988) and after (1989 through 1990) institution of the New York State triplicate benzodiazepine regulations.
Data Sources.
—The National Prescription Audit (IMS America, Plymouth Meeting, Pa), New York State Medicaid, and Blue Cross/Blue Shield of the Rochester (NY) Area.
Results.
—From 1988 to 1989, New York State benzodiazepine prescribing decreased by 44%, 60%, and 30% as assessed by IMS America, Medicaid, and Blue Cross/Blue Shield, respectively. Prescribing of the following alternative sedative-hypnotics increased in New York State compared with decreases nationally (IMS America data): meprobamate, +125% vs -9%; methyprylon, +84% vs -15%; ethchlorvynol, +29% vs -18%; butabarbital, +31% vs -15%; hydroxyzine, +15% vs -1.1%; and chloral hydrate, +136% vs - 0.4%. Increased prescribing of alternatives was also seen in the Medicaid and Blue Cross/Blue Shield data. Medicaid benzodiazepine expenditures decreased 52% from 1988 to 1989 ($21.7 million to $10.4 million). Alternative sedative expenditures increased 115% ($3.9 million to $8.4 million). Total Medicaid psychoactive medication expenditures remained nearly constant ($46.7 million to $45.6 million).
Conclusion.
—Although the triplicate regulations have decreased benzodiazepine prescribing, an undesirable increase has occurred in the prescribing of less acceptable medications. The wider public health, patient care, and financial implications of triplicate benzodiazepine regulations are of concern and require further study before other jurisdictions undertake similar programs.
(JAMA. 1991;266:2392-2397)
Author Affiliations
From the Departments of Community and Preventive Medicine (Drs Weintraub and Singh and Ms Byrne), and Psychiatry (Mr Maharaj and Dr Guttmacher), University of Rochester School of Medicine and Dentistry, Rochester, NY.
Footnotes
Presented, in part, at the annual meeting of the American Society of Clinical Pharmacology and Therapeutics, San Antonio, Tex, March 14,1991.
Reprint requests to Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Box 644, 601 Elmwood Ave, Rochester, NY 14642 (Dr Weintraub).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Consequences of a benzodiazepine discontinuation programme in family practice on psychotropic medication prescription to the participants
Gorgels et al.
Fam Pract 2007;24:504-510.
ABSTRACT
| FULL TEXT
Effect of New York State Regulatory Action on Benzodiazepine Prescribing and Hip Fracture Rates
Wagner et al.
ANN INTERN MED 2007;146:96-103.
ABSTRACT
| FULL TEXT
Effects of state surveillance on new post-hospitalization benzodiazepine use
Wagner et al.
Int J Qual Health Care 2003;15:423-431.
ABSTRACT
| FULL TEXT
Legislation and End-of-Life Care
Gloth III et al.
JAMA 2000;283:2933-2933.
FULL TEXT
Taking Policy Action to Reduce Benzodiazepine Use and Promote Self-Care Among Seniors
Hall
Journal of Applied Gerontology 1998;17:318-351.
ABSTRACT
Prescribing Trends in Psychotropic Medications: Primary Care, Psychiatry, and Other Medical Specialties
Pincus et al.
JAMA 1998;279:526-531.
ABSTRACT
| FULL TEXT
Medication-Prescribing Errors in a Teaching Hospital: A 9-Year Experience
Lesar et al.
Arch Intern Med 1997;157:1569-1576.
ABSTRACT
Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid Patients
Smalley et al.
NEJM 1995;332:1612-1617.
ABSTRACT
| FULL TEXT
Use of Benzodiazepines in the Community
Olfson and Pincus
Arch Intern Med 1994;154:1235-1240.
ABSTRACT
Examining Product Risk in Context: Market Withdrawal of Zomepirac as a Case Study
Ross-Degnan et al.
JAMA 1993;270:1937-1942.
ABSTRACT
Benzodiazepine Prescription Regulations
Sampson
JAMA 1992;268:3316-3316.
ABSTRACT
Benzodiazepine Prescription Regulations-Reply
Weintraub
JAMA 1992;268:3316-3317.
ABSTRACT
Prescription Drug Diversion Control and Medical Practice
Cooper et al.
JAMA 1992;268:1306-1310.
ABSTRACT
Regulation of Benzodiazepine Prescription
Levin
JAMA 1992;268:473-473.
ABSTRACT
Regulation of Benzodiazepine Prescription-Reply
Glass
JAMA 1992;268:474-474.
ABSTRACT
Benzodiazepine Prescription Regulation: Autonomy and Outcome
Glass
JAMA 1991;266:2431-2433.
ABSTRACT
|
